Recent News

• 02.05.2026 - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.02.2026 - Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
• 01.26.2026 - Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
• 01.22.2026 - Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
• 01.21.2026 - Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
• 01.12.2026 - Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Recent Filings

• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 144 Report of proposed sale of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 144 Report of proposed sale of securities
• 02.02.2026 - 144 Report of proposed sale of securities
• 02.02.2026 - 144 Report of proposed sale of securities